Christof Scheid1, Igor W Blau2, Leopold Sellner3, Boris A Ratsch3, Edin Basic3. 1. Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany. 2. Charité University Medicine Berlin, Berlin, Germany. 3. Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany.
Abstract
OBJECTIVES: Emerging treatments for relapsed or refractory multiple myeloma (rrMM) have led to increasing options for many patients. This study aimed to assess changes in utilization of these options in Germany with a focus on modern triplet regimens including new agents, such as carfilzomib, ixazomib, elotuzumab and daratumumab, and to evaluate whether this had an impact on rrMM-related outcomes over time. METHODS: The study population consisted of 1255 rrMM patients who were assigned to one of the following 6 treatment groups: immunomodulatory drug (IMiD)-based doublets, proteasome inhibitor (PI)-based doublets, daratumumab monotherapy, PI-IMiD-based triplets, monoclonal antibodies (mAbs)-based triplets, or other treatment. RESULTS: Use of triplet-based therapy regimens increased from 5.9% in 2014 to 31.4% in 2017. In parallel, use of IMiD-based doublets decreased from 74.3% in 2014 to 37.6% in 2017. Over the same time period, the risk of death decreased by 32% and the risk of hospitalization which was reduced by 30%. The risk for serious adverse events remained unchanged. CONCLUSIONS: Between 2014 and 2017, the use of triplet-based therapy regimens for rrMM in Germany has significantly increased and this was associated with a significant decline in deaths and hospitalizations without an increased incidence of serious adverse events.
OBJECTIVES: Emerging treatments for relapsed or refractory multiple myeloma (rrMM) have led to increasing options for many patients. This study aimed to assess changes in utilization of these options in Germany with a focus on modern triplet regimens including new agents, such as carfilzomib, ixazomib, elotuzumab and daratumumab, and to evaluate whether this had an impact on rrMM-related outcomes over time. METHODS: The study population consisted of 1255 rrMM patients who were assigned to one of the following 6 treatment groups: immunomodulatory drug (IMiD)-based doublets, proteasome inhibitor (PI)-based doublets, daratumumab monotherapy, PI-IMiD-based triplets, monoclonal antibodies (mAbs)-based triplets, or other treatment. RESULTS: Use of triplet-based therapy regimens increased from 5.9% in 2014 to 31.4% in 2017. In parallel, use of IMiD-based doublets decreased from 74.3% in 2014 to 37.6% in 2017. Over the same time period, the risk of death decreased by 32% and the risk of hospitalization which was reduced by 30%. The risk for serious adverse events remained unchanged. CONCLUSIONS: Between 2014 and 2017, the use of triplet-based therapy regimens for rrMM in Germany has significantly increased and this was associated with a significant decline in deaths and hospitalizations without an increased incidence of serious adverse events.
Authors: Antonio Palumbo; Asher Chanan-Khan; Katja Weisel; Ajay K Nooka; Tamas Masszi; Meral Beksac; Ivan Spicka; Vania Hungria; Markus Munder; Maria V Mateos; Tomer M Mark; Ming Qi; Jordan Schecter; Himal Amin; Xiang Qin; William Deraedt; Tahamtan Ahmadi; Andrew Spencer; Pieter Sonneveld Journal: N Engl J Med Date: 2016-08-25 Impact factor: 91.245
Authors: A Keith Stewart; S Vincent Rajkumar; Meletios A Dimopoulos; Tamás Masszi; Ivan Špička; Albert Oriol; Roman Hájek; Laura Rosiñol; David S Siegel; Georgi G Mihaylov; Vesselina Goranova-Marinova; Péter Rajnics; Aleksandr Suvorov; Ruben Niesvizky; Andrzej J Jakubowiak; Jesus F San-Miguel; Heinz Ludwig; Michael Wang; Vladimír Maisnar; Jiri Minarik; William I Bensinger; Maria-Victoria Mateos; Dina Ben-Yehuda; Vishal Kukreti; Naseem Zojwalla; Margaret E Tonda; Xinqun Yang; Biao Xing; Philippe Moreau; Antonio Palumbo Journal: N Engl J Med Date: 2014-12-06 Impact factor: 91.245
Authors: Jatin J Shah; Rafat Abonour; Christina Gasparetto; James W Hardin; Kathleen Toomey; Mohit Narang; Shankar Srinivasan; Amani Kitali; Faiza Zafar; E Dawn Flick; Robert M Rifkin Journal: Clin Lymphoma Myeloma Leuk Date: 2017-06-17
Authors: Philippe Moreau; Tamás Masszi; Norbert Grzasko; Nizar J Bahlis; Markus Hansson; Ludek Pour; Irwindeep Sandhu; Peter Ganly; Bartrum W Baker; Sharon R Jackson; Anne-Marie Stoppa; David R Simpson; Peter Gimsing; Antonio Palumbo; Laurent Garderet; Michele Cavo; Shaji Kumar; Cyrille Touzeau; Francis K Buadi; Jacob P Laubach; Deborah T Berg; Jianchang Lin; Alessandra Di Bacco; Ai-Min Hui; Helgi van de Velde; Paul G Richardson Journal: N Engl J Med Date: 2016-04-28 Impact factor: 91.245
Authors: Edward S Kim; Suanna S Bruinooge; Samantha Roberts; Gwynn Ison; Nancy U Lin; Lia Gore; Thomas S Uldrick; Stuart M Lichtman; Nancy Roach; Julia A Beaver; Rajeshwari Sridhara; Paul J Hesketh; Andrea M Denicoff; Elizabeth Garrett-Mayer; Eric Rubin; Pratik Multani; Tatiana M Prowell; Caroline Schenkel; Marina Kozak; Jeff Allen; Ellen Sigal; Richard L Schilsky Journal: J Clin Oncol Date: 2017-10-02 Impact factor: 44.544
Authors: David S Siegel; Meletios A Dimopoulos; Heinz Ludwig; Thierry Facon; Hartmut Goldschmidt; Andrzej Jakubowiak; Jesus San-Miguel; Mihaela Obreja; Julie Blaedel; A Keith Stewart Journal: J Clin Oncol Date: 2018-01-17 Impact factor: 44.544
Authors: Amal AlZahmi; Irena Cenzer; Ulrich Mansmann; Helmut Ostermann; Sebastian Theurich; Tobias Schleinkofer; Karin Berger Journal: PLoS One Date: 2022-07-28 Impact factor: 3.752